BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 16350834)

  • 21. [Neurological manifestations of Fabry disease].
    Mendióroz M; Fernández-Cadenas I; Montaner J
    Rev Neurol; 2006 Dec 16-31; 43(12):739-45. PubMed ID: 17160925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kidney transplantation and enzyme replacement therapy in patients with Fabry disease.
    Cybulla M; Kurschat C; West M; Nicholls K; Torras J; Sunder-Plassmann G; Feriozzi S
    J Nephrol; 2013; 26(4):645-51. PubMed ID: 23023720
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Control of proteinuria with increased doses of agalsidase alfa in a patient with Fabry disease with atypical genotype-phenotype expression.
    Paliouras C; Aperis G; Lamprianou F; Ntetskas G; Roufas K; Alivanis P
    Nefrologia; 2015; 35(6):578-81. PubMed ID: 26384850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes.
    Kim JH; Lee BH; Hyang Cho J; Kang E; Choi JH; Kim GH; Yoo HW
    J Hum Genet; 2016 Nov; 61(11):923-929. PubMed ID: 27334365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rare presentation of Fabry disease as 'burnt-out' hypertrophic cardiomyopathy.
    Williams S; El-Medany A; Nightingale A; Ismail Y
    BMJ Case Rep; 2021 Sep; 14(9):. PubMed ID: 34479887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Neurological complications of Fabry-disease].
    Vastagh I; Constantin T; Kéri A; Rudas G; Fekete G; Bereczki D
    Ideggyogy Sz; 2011 Jan; 64(1-2):29-35. PubMed ID: 21428036
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnosis and management of kidney involvement in Fabry disease.
    Warnock DG; West ML
    Adv Chronic Kidney Dis; 2006 Apr; 13(2):138-47. PubMed ID: 16580615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy.
    Desnick RJ; Brady R; Barranger J; Collins AJ; Germain DP; Goldman M; Grabowski G; Packman S; Wilcox WR
    Ann Intern Med; 2003 Feb; 138(4):338-46. PubMed ID: 12585833
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Fabry disease--a provocation for pediatrics].
    Hoffmann B; Mayatepek E
    Klin Padiatr; 2006; 218(1):38-40. PubMed ID: 16432775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Fabry nephropathy in a female with superposed IgA glomerulonephritis].
    Pisani A; Sessa A; Sabbatini M; Andreucci MV; Fusco C; Balletta M; Cianciaruso B
    G Ital Nefrol; 2005; 22(4):385-9. PubMed ID: 16267800
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Cardiac manifestations of Anderson-Fabry disease and efficacy of enzyme replacement therapy].
    Hagège A
    Rev Med Interne; 2010 Dec; 31 Suppl 2():S238-42. PubMed ID: 21211672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Enzyme replacement therapy in Fabry's disease].
    Alvarez L; del Pozo C; Trigueros M; Sánchez L; Albero MD; López-Menchero R; Ortega E
    Nefrologia; 2005; 25(3):322-7. PubMed ID: 16053014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fabry disease with atypical neurological presentation: report of a case.
    Simoncini C; Orsucci D; Gori S; Giorgi FS; Cosottini M; Siciliano G; Mancuso M
    Neurologist; 2012 Nov; 18(6):413-4. PubMed ID: 23114679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Severe hypertrophic cardiomyopathy in a patient with atypical Anderson-Fabry disease.
    Masarone D; Duro G; Dellegrottaglie S; Colomba P; Rubino M; Cirillo A; Pisani A; Caiazza M; Elliott PM; Calabrò P; Pacileo G; Limongelli G
    Future Cardiol; 2017 Nov; 13(6):521-527. PubMed ID: 28936893
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enzyme replacement therapy and Fabry nephropathy.
    Warnock DG; Daina E; Remuzzi G; West M
    Clin J Am Soc Nephrol; 2010 Feb; 5(2):371-8. PubMed ID: 20007680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy.
    Ortiz A; Oliveira JP; Waldek S; Warnock DG; Cianciaruso B; Wanner C;
    Nephrol Dial Transplant; 2008 May; 23(5):1600-7. PubMed ID: 18175781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The heart in Anderson Fabry disease.
    Kampmann C; Wiethoff CM; Perrot A; Beck M; Dietz R; Osterziel KJ
    Z Kardiol; 2002 Oct; 91(10):786-95. PubMed ID: 12395219
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enzyme replacement therapy and Fabry kidney disease: quo vadis?
    Warnock DG
    J Am Soc Nephrol; 2007 May; 18(5):1368-70. PubMed ID: 17429046
    [No Abstract]   [Full Text] [Related]  

  • 39. Fabry disease: enzyme replacement therapy.
    Bongiorno MR; Pistone G; Aricò M
    J Eur Acad Dermatol Venereol; 2003 Nov; 17(6):676-9. PubMed ID: 14761135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neurological complications in Fabry disease.
    Dütsch M; Hilz MJ
    Rev Med Interne; 2010 Dec; 31 Suppl 2():S243-50. PubMed ID: 21211673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.